{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:21:17Z","timestamp":1793146877262,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to assess how Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) influences lung function, Body Mass Index (BMI), Sweat Test (ST) and mental health of Cystic Fibrosis (CF) patients, emphasizing on depression and anxiety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an observational, prospective, multicentre study including 108 patients over 18 years old who initiated ETI therapy between December 2019 and December 2023. Patients underwent regular evaluations, including clinical, functional, and microbiological assessments, alongside completion of quality of life, anxiety, and depression questionnaires. We evaluated whether there was a difference in anxiety and depression levels over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 12 months of treatment, significant improvements were noted in BMI, lung function (FEV1%), ST and various aspects of quality of life (CFQ-R). However, anxiety and depression levels did not differ significantly during the follow-up. When we stratified our sample by key groups, we observed that younger patients (under 28 years) and those with homozygous Phe508del mutations experienced significant higher anxiety with no differences on depression. Furthermore, anxiety and depression demonstrated a moderate correlation, strengthening over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with ETI establishes significant improvements in lung function, BMI, ST and quality of life in patients with CF. However, despite these positive outcomes, there were no significant changes observed in levels of anxiety and depression, except for individuals with homozygous mutation type and those younger than 28 years old, who exhibited significant higher levels of anxiety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-024-03455-2","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:11:03Z","timestamp":1739751063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unveiling the psychosocial impact of Elexacaftor\/Tezacaftor\/Ivacaftor therapy in Cystic Fibrosis patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Marta Sol\u00eds","family":"Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Pel\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Mar G\u00f3mez","family":"Punter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Criado","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Madrid","family":"Carbajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ancochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Mar\u00eda Eiros","family":"Bachiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sof\u00eda Mart\u00edn","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rodrigo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Garc\u00eda","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M\u00aa Gir\u00f3n","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"3455_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","volume":"58","author":"JS Talwalkar","year":"2017","unstructured":"Talwalkar JS, Koff JL, Lee HB, et al. Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis. Psychosomatics. 2017;58:343\u201354.","journal-title":"Psychosomatics"},{"issue":"3","key":"3455_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/children10030554","volume":"10","author":"N Kapouni","year":"2023","unstructured":"Kapouni N, Moustaki M, Douros K, Loukou I. Efficacy and safety of Elexacaftor-Tezacaftor-Ivacaftor in the treatment of cystic fibrosis: a systematic review. Child (Basel). 2023;10(3):554. https:\/\/doi.org\/10.3390\/children10030554. PMID: 36980112; PMCID: PMC10047761.","journal-title":"Child (Basel)"},{"key":"3455_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","volume":"71","author":"AL Quittner","year":"2016","unstructured":"Quittner AL, Abbott J, Georgiopoulos AM, et al. International committee on mental health in cystic fibrosis: cystic fibrosis foundation and European cystic fibrosis society consensus statements for screening and treating depression and anxiety. Thorax. 2016;71:26\u201334.","journal-title":"Thorax"},{"key":"3455_CR4","doi-asserted-by":"crossref","unstructured":"Heijerman HG, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. The Lancet. 2019;23(394(10212)):1940\u20138.","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"3455_CR5","unstructured":"Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, et al. French cystic fibrosis reference network study group. Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease.\u00a0Am J Respir Crit Care Med. 2021;(204):64\u201373."},{"issue":"9","key":"3455_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.arbres.2023.05.017","volume":"59","author":"L Carrasco Hern\u00e1ndez","year":"2023","unstructured":"Carrasco Hern\u00e1ndez L, Gir\u00f3n Moreno RM, Balaguer Cartagena MN, Pel\u00e1ez A, Sole A, \u00c1lvarez Fern\u00e1ndez A, et al. Experience with Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis and advanced disease. Arch Bronconeumol. 2023;59(9):556\u201365.","journal-title":"Arch Bronconeumol"},{"key":"3455_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","volume":"16","author":"CJ McKinzie","year":"2017","unstructured":"McKinzie CJ, Goralski JL, Noah TL, et al. Worsening anxiety and depression after initiation of lumacaftor\/ivacaftor combination therapy in adolescent females with cystic fibrosis. J Cyst Fibros. 2017;16:525\u20137.","journal-title":"J Cyst Fibros"},{"key":"3455_CR8","doi-asserted-by":"publisher","first-page":"102214","DOI":"10.1016\/j.coph.2022.102214","volume":"64","author":"G Cabrini","year":"2022","unstructured":"Cabrini G, Rimessi A, Borgatti M, Pinton P, Gambari R. Overview of CF lung pathophysiology. Curr Opin Pharmacol. 2022;64: 102214. https:\/\/doi.org\/10.1016\/j.coph.2022.102214. Epub 2022 Apr 19. PMID: 35453033.","journal-title":"Curr Opin Pharmacol"},{"key":"3455_CR9","unstructured":"Quintana-Gallego E. Editorial fibrosis qu\u00edstica: asociaci\u00f3n entre depresi\u00f3n, ansiedad y calidad de vida relacionada con la salud. 2012."},{"issue":"4","key":"3455_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.arbres.2013.07.013","volume":"50","author":"E Quintana-Gallego","year":"2014","unstructured":"Quintana-Gallego E, Delgado-Pecell\u00edn I, Calero Acu\u00f1a C. Tratamientos reparadores de la prote\u00edna CFTR en la fibrosis qu\u00edstica. Arch Bronconeumol. 2014;50(4):146\u201350.","journal-title":"Arch Bronconeumol"},{"issue":"9","key":"3455_CR11","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/ppul.26527","volume":"58","author":"CJ Bathgate","year":"2023","unstructured":"Bathgate CJ, Muther E, Georgiopoulos AM, Smith B, Tillman L, Graziano S, Verkleij M, Lomas P, Quittner A. Positive and negative impacts of elexacaftor\/tezacaftor\/ivacaftor: Healthcare providers\u2019 observations across US centers. Pediatr Pulmonol. 2023;58(9):2469\u201377 Epub 2023 Jun 2. PMID: 37265418.","journal-title":"Pediatr Pulmonol"},{"key":"3455_CR12","doi-asserted-by":"crossref","unstructured":"Martin C, Burnet E, Ronayette-Preira A, de Carli P, Martin J, Delmas L, et al. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. Respir Med Res. 2021;80:100829.","DOI":"10.1016\/j.resmer.2021.100829"},{"issue":"4","key":"3455_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.arbres.2010.01.006","volume":"46","author":"G Olveira","year":"2010","unstructured":"Olveira G, Olveira C, Gaspar I, Cruz I, Dorado A, P\u00e9rez-Ruiz E, et al. Validaci\u00f3n De La versi\u00f3n espa\u00f1ola del cuestionario revisado de calidad de vida para fibrosis qu\u00edstica en adolescentes y adultos (CFQR 14\u2009+\u2009Spain). Arch Bronconeumol. 2010;46(4):165\u201375.","journal-title":"Arch Bronconeumol"},{"key":"3455_CR14","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","volume":"282","author":"RL Spitzer","year":"1999","unstructured":"Spitzer RL, Kroenke K, Williams JBW, Patient Health Questionnaire Study Group. Validity and utility of a self-report version of PRIMEMD: the PHQ Primary Care Study. JAMA. 1999;282:1737\u201344.","journal-title":"JAMA"},{"issue":"9","key":"3455_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"key":"3455_CR16","doi-asserted-by":"publisher","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940\u20131948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8. Epub 2019 Oct 31. Erratum in: Lancet. 2020;395(10238):1694. PMID: 31679946; PMCID: PMC7571408.","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"3455_CR17","doi-asserted-by":"publisher","unstructured":"Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, Ellemunter H, Dittrich AM, Smaczny C, Eickmeier O, Kappler M, Schwarz C, Sieber S, Naehrig S, Naehrlich L, German. Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Health Eur. 2023;32:100690. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100690. PMID: 37554663; PMCID: PMC10405057. CF Registry of the Mukoviszidose e.V. and participating CF sites.","DOI":"10.1016\/j.lanepe.2023.100690"},{"issue":"4","key":"3455_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","volume":"22","author":"JK Bower","year":"2023","unstructured":"Bower JK, Volkova N, Ahluwalia N, Sahota G, Xuan F, Chin A, Weinstock TG, Ostrenga J, Elbert A. Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study. J Cyst Fibros. 2023;22(4):730\u20137 Epub 2023 Mar 22. PMID: 36963986.","journal-title":"J Cyst Fibros"},{"issue":"11","key":"3455_CR19","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cells11111769","volume":"11","author":"L Regard","year":"2022","unstructured":"Regard L, Martin C, Burnet E, Da Silva J, Burgel PR. CFTR modulators in people with cystic fibrosis: real-world evidence in France. Cells. 2022;11(11):1769. https:\/\/doi.org\/10.3390\/cells11111769. PMID: 35681464; PMCID: PMC9179538.","journal-title":"Cells"},{"key":"3455_CR20","doi-asserted-by":"publisher","first-page":"175346662211442","DOI":"10.1177\/17534666221144211","volume":"16","author":"L Zhang","year":"2022","unstructured":"Zhang L, Albon D, Jones M, Bruschwein H. Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis. Ther Adv Respir Dis. 2022;16:17534666221144212. https:\/\/doi.org\/10.1177\/17534666221144211. PMID: 36562554; PMCID: PMC9793010.","journal-title":"Ther Adv Respir Dis"},{"issue":"9","key":"3455_CR21","doi-asserted-by":"publisher","first-page":"e70007","DOI":"10.1111\/crj.70007","volume":"18","author":"H Pudukodu","year":"2024","unstructured":"Pudukodu H, Powell MZ, Ceppe A, Donaldson SH, Goralski JL, Sowa NA. Analysis of depression and anxiety scores following initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis. Clin Respir J. 2024;18(9):e70007. https:\/\/doi.org\/10.1111\/crj.70007. PMID: 39210645; PMCID: PMC11362501.","journal-title":"Clin Respir J"},{"issue":"3","key":"3455_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","volume":"209","author":"B Ramsey","year":"2024","unstructured":"Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, Tian S, Mall MA. Elexacaftor\/Tezacaftor\/Ivacaftor treatment and depression-related events. Am J Respir Crit Care Med. 2024;209(3):299\u2013306. https:\/\/doi.org\/10.1164\/rccm.202308-1525OC. PMID: 37890129; PMCID: PMC10840763.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3455_CR23","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/ppul.26412","volume":"58","author":"E Baroud","year":"2023","unstructured":"Baroud E, Chaudhary N, Georgiopoulos AM. Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor. Pediatr Pulmonol. 2023;58(7):1920\u201330. https:\/\/doi.org\/10.1002\/ppul.26412. Epub 2023 Apr 10. PMID: 37036050.","journal-title":"Pediatr Pulmonol"},{"key":"3455_CR24","doi-asserted-by":"publisher","first-page":"107095","DOI":"10.1016\/j.rmed.2022.107095","volume":"207","author":"S Graziano","year":"2023","unstructured":"Graziano S, Ullmann N, Rusciano R, Allegorico A, Boldrini F, Rosito L, Quittner AL, Cutrera R, Tabarini P. Comparison of mental health in individuals with primary ciliary dyskinesia, cystic fibrosis, and parent caregivers. Respir Med. 2023;207: 107095 Epub 2022 Dec 23. PMID: 36572068.","journal-title":"Respir Med"},{"key":"3455_CR25","doi-asserted-by":"publisher","first-page":"100280","DOI":"10.1016\/j.jcte.2021.100280","volume":"26","author":"A Darukhanavala","year":"2021","unstructured":"Darukhanavala A, Merjaneh L, Mason K, Le T. Eating disorders and body image in cystic fibrosis. J Clin Transl Endocrinol. 2021;26: 100280. https:\/\/doi.org\/10.1016\/j.jcte.2021.100280. PMID: 34917482; PMCID: PMC8646158.","journal-title":"J Clin Transl Endocrinol"},{"issue":"5","key":"3455_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/jhn.12967","volume":"35","author":"J Barrett","year":"2022","unstructured":"Barrett J, Slatter G, Whitehouse JL, Nash EF. Perception, experience and relationship with food and eating in adults with cystic fibrosis. J Hum Nutr Diet. 2022;35(5):757\u201364. https:\/\/doi.org\/10.1111\/jhn.12967. Epub 2021 Dec 16. PMID: 34914145.","journal-title":"J Hum Nutr Diet"},{"issue":"8742","key":"3455_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0140-6736(91)92449-c","volume":"337","author":"HK Johansen","year":"1991","unstructured":"Johansen HK, Nir M, H\u00f8iby N, Koch C, Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet. 1991;337(8742):631\u20134. https:\/\/doi.org\/10.1016\/0140-6736(91)92449-c. PMID: 1671990.","journal-title":"Lancet."},{"issue":"18","key":"3455_CR28","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.3390\/nu16183103","volume":"16","author":"M Sol\u00eds-Garc\u00eda","year":"2024","unstructured":"Sol\u00eds-Garc\u00eda M, Garc\u00eda-Clemente MM, Madrid-Carbajal CJ, et al. Is obesity a problem in new cystic fibrosis treatments? Nutrients. 2024;16(18):3103. https:\/\/doi.org\/10.3390\/nu16183103. Published 2024 Sep 14.","journal-title":"Nutrients"},{"issue":"2","key":"3455_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022;21(2):265\u201371. https:\/\/doi.org\/10.1016\/j.jcf.2021.11.012.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"3455_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","volume":"22","author":"I Fajac","year":"2023","unstructured":"Fajac I, Daines C, Durieu I, Goralski JL, Heijerman H, Knoop C, Majoor C, Bruinsma BG, Moskowitz S, Prieto-Centurion V, Van Brunt K, Zhang Y, Quittner A. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor. J Cyst Fibros. 2023;22(1):119\u201323 Epub 2022 Sep 14. PMID: 36114142.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"3455_CR31","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","volume":"22","author":"D Proud","year":"2023","unstructured":"Proud D, Duckers J. Weight a minute: exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF. J Cyst Fibros. 2023;22(5):847\u201350. https:\/\/doi.org\/10.1016\/j.jcf.2023.06.002.","journal-title":"J Cyst Fibros"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03455-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:11:08Z","timestamp":1739751068000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03455-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3455"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03455-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4754430\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of both hospitals (CEIm Ref No\n                      957\/2020\n                      and\n                      067\/2020\n                      )\u201d for studies involving humans, and informed consent was obtained every human participant in this study. The informed consent was included in supplementary data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not contain any individual data, therefore consent for publication is \u201cNot applicable\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}